Literature DB >> 10070329

The expression of beta-catenin in non-small-cell lung cancer: a clinicopathological study.

J M Retera1, M P Leers, M A Sulzer, P H Theunissen.   

Abstract

AIMS: To investigate the expression of beta-catenin in non-small-cell lung cancer (NSCLC) and its clinical significance.
METHODS: 101 patients were surgically treated for NSCLC by lobectomy or pneumectomy with systematic lymph node dissection. Follow up was available in all patients, ranging from 24 to 110 months. Immunostaining of tissue sections from primary tumours and (when present) their lymph node metastases was performed and evaluated using a monoclonal antibody against beta-catenin. Correlations were investigated between beta-catenin immunostaining in primary tumours and E-cadherin immunostaining (data available from a previous study), lymph node stage, and survival.
RESULTS: There were significant correlations between scores for beta-catenin immunostaining and E-cadherin immunostaining in primary tumours (p = 0.007), and between the beta-catenin immunostaining score in primary tumours and in their lymph node metastases (p = 0.006). An inverse correlation was found between the beta-catenin immunostaining score in primary tumours and lymph node stage N0, N1, or N2 (p = 0.03). According to the Kaplan-Meier survival estimate, the level of beta-catenin expression in primary tumours was a statistically significant prognostic factor (p = 0.01).
CONCLUSIONS: Reduced beta-catenin expression in surgically treated NSCLC is clearly associated with lymph node metastasis and an infavourable prognosis. The existence of a functional relation between E-cadherin and beta-catenin is supported by the results of this clinicopathological study.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10070329      PMCID: PMC501023          DOI: 10.1136/jcp.51.12.891

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  11 in total

1.  Expression of E-cadherin, alpha, beta and gamma-catenin in human colorectal cancer.

Authors:  S Hiscox; W G Jiang
Journal:  Anticancer Res       Date:  1997 Mar-Apr       Impact factor: 2.480

2.  Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis.

Authors:  K K Krishnadath; H W Tilanus; M van Blankenstein; W C Hop; E D Kremers; W N Dinjens; F T Bosman
Journal:  J Pathol       Date:  1997-07       Impact factor: 7.996

Review 3.  Regulation of the invasion suppressor function of the cadherin/catenin complex.

Authors:  S Vermeulen; V Van Marck; L Van Hoorde; F Van Roy; M Bracke; M Mareel
Journal:  Pathol Res Pract       Date:  1996-07       Impact factor: 3.250

4.  Association of the APC gene product with beta-catenin.

Authors:  B Rubinfeld; B Souza; I Albert; O Müller; S H Chamberlain; F R Masiarz; S Munemitsu; P Polakis
Journal:  Science       Date:  1993-12-10       Impact factor: 47.728

5.  Expression of E-cadherin and catenins in invasive mammary carcinomas.

Authors:  W Zschiesche; I Schönborn; J Behrens; K Herrenknecht; F Hartveit; P Lilleng; W Birchmeier
Journal:  Anticancer Res       Date:  1997 Jan-Feb       Impact factor: 2.480

Review 6.  Cadherin and catenin biology represent a global mechanism for epithelial cancer progression.

Authors:  J A Jankowski; R Bruton; N Shepherd; D S Sanders
Journal:  Mol Pathol       Date:  1997-12

7.  Beta-catenin expression in human cancers.

Authors:  T Takayama; H Shiozaki; S Shibamoto; H Oka; Y Kimura; S Tamura; M Inoue; T Monden; F Ito; M Monden
Journal:  Am J Pathol       Date:  1996-01       Impact factor: 4.307

8.  Mediastinal lymph node dissection in resected lung cancer: morbidity and accuracy of staging.

Authors:  E C Bollen; C J van Duin; P H Theunissen; B E vt Hof-Grootenboer; G H Blijham
Journal:  Ann Thorac Surg       Date:  1993-04       Impact factor: 4.330

Review 9.  E-cadherin mediated adhesion system in cancer cells.

Authors:  H Shiozaki; H Oka; M Inoue; S Tamura; M Monden
Journal:  Cancer       Date:  1996-04-15       Impact factor: 6.860

10.  Loss of E-cadherin-dependent cell-cell adhesion due to mutation of the beta-catenin gene in a human cancer cell line, HSC-39.

Authors:  J Kawanishi; J Kato; K Sasaki; S Fujii; N Watanabe; Y Niitsu
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

View more
  23 in total

1.  Nuclear beta catenin expression is related to unfavourable outcome in oropharyngeal and hypopharyngeal squamous cell carcinoma.

Authors:  M J Pukkila; J A Virtaniemi; E J Kumpulainen; R T Pirinen; R T Johansson; H J Valtonen; M T Juhola; V M Kosma
Journal:  J Clin Pathol       Date:  2001-01       Impact factor: 3.411

2.  Expression of RKIP, E-cadherin and NF-kB p65 in esophageal squamous cell carcinoma and their correlations.

Authors:  Fu-Min Ping; Gui-Jing Liu; Zhi-Jun Liu; Hai-Bin Li; Jian-Wen Zhai; Shu-Xia Li; Yue-Mei Liu; Bao-Wei Li; Hong Wei
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

3.  Reduced expression of alpha-catenin, beta-catenin, and gamma-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer.

Authors:  R T Pirinen; P Hirvikoski; R T Johansson; S Hollmén; V M Kosma
Journal:  J Clin Pathol       Date:  2001-05       Impact factor: 3.411

Review 4.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

5.  Proliferation, but not apoptosis, is associated with distinct beta-catenin expression patterns in non-small-cell lung carcinomas: relationship with adenomatous polyposis coli and G(1)-to S-phase cell-cycle regulators.

Authors:  Athamassios Kotsinas; Konstantinos Evangelou; Panayotis Zacharatos; Christos Kittas; Vassilis G Gorgoulis
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

6.  Prognostic value of β-catenin, c-myc, and cyclin D1 expressions in patients with esophageal squamous cell carcinoma.

Authors:  Wei Wang; Lexun Xue; Pengju Wang
Journal:  Med Oncol       Date:  2010-02-09       Impact factor: 3.064

7.  Clinicopathologic significance of β-catenin and matrix metalloproteinase-2 expression in non-small cell lung cancer.

Authors:  Guang-Hu Li; Yong-Sheng Cui; Qi-Yu Wu; Xiong-Ji Zhang; Yu-Fei Gao
Journal:  Med Oncol       Date:  2013-01-05       Impact factor: 3.064

8.  Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancer.

Authors:  Mark Shapiro; Gal Akiri; Cynthia Chin; Juan P Wisnivesky; Mary B Beasley; Todd S Weiser; Scott J Swanson; Stuart A Aaronson
Journal:  Ann Surg       Date:  2013-03       Impact factor: 12.969

9.  WNT/β-catenin signaling regulates cigarette smoke-induced airway inflammation via the PPARδ/p38 pathway.

Authors:  Lingli Guo; Tao Wang; Yanqiu Wu; Zhicheng Yuan; Jiajia Dong; Xiao'ou Li; Jing An; Zenglin Liao; Xue Zhang; Dan Xu; Fu-Qiang Wen
Journal:  Lab Invest       Date:  2015-08-31       Impact factor: 5.662

10.  WNT7a induces E-cadherin in lung cancer cells.

Authors:  Tatsuo Ohira; Robert M Gemmill; Kevin Ferguson; Sophie Kusy; Joëlle Roche; Elisabeth Brambilla; Chan Zeng; Anna Baron; Lynne Bemis; Paul Erickson; Elizabeth Wilder; Anil Rustgi; Jan Kitajewski; Edward Gabrielson; Roy Bremnes; Wilbur Franklin; Harry A Drabkin
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.